中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
8期
1071-1072
,共2页
熊宁%彭志群%吴金飞%王强%陈传琳%吴珊燕
熊寧%彭誌群%吳金飛%王彊%陳傳琳%吳珊燕
웅저%팽지군%오금비%왕강%진전림%오산연
苏黄止咳胶囊%咳嗽变异性哮喘%气道高反应性
囌黃止咳膠囊%咳嗽變異性哮喘%氣道高反應性
소황지해효낭%해수변이성효천%기도고반응성
Suhuang zhike capsule%Cough variant asthma%Airway hyperresponsiveness
目的 观察苏黄止咳胶囊治疗咳嗽变异性哮喘的临床疗效.方法 将80例咳嗽变异性哮喘患者完全随机分为2组,各40例.苏黄止咳胶囊组予以苏黄止咳胶囊,每次3粒,每日3次,温开水送服；博利康尼组予以博利康尼2.5 mg,每日3次.疗程均为4周.比较2组患者疗效和治疗前后IgG水平及气道阻力后.结果 苏黄止咳胶囊组治愈37例,好转3例,治愈率为92.5％；博利康尼组治愈29例,好转11例,治愈率为72.5％；苏黄止咳胶囊组治愈率明显高于博利康尼组,差异有统计学意义(P＜0.05).苏黄止咳胶囊组治疗前IgG水平为(6.4 ±3.2)g/L,治疗后为(8.8 ±4.7)g/L,治疗前后差异有统计学意义(P＜0.05)；博利康尼组治疗前IgG为(6.5±2.9)g/L,治疗后为(7.2±3.8) g/L,治疗前后差异无统计学意义(P＞0.05)；苏黄止咳胶囊组治疗后IgG水平明显高于博利康尼组治疗后(P＜0.05).苏黄止咳胶囊组治疗后呼吸总阻抗、总气道阻力、中心气道阻力均明显低于博利康尼组治疗后[(122±36)cm H2O(1 cm H2O=0.098 kPa)比(144±41)cm H2O,(118±32)cm H2O比(142 ±35)cm H2O,(83±26)cm H2O比(100±24)cm H2O],差异均有统计学意义(均P＜0.01).结论 苏黄止咳胶囊治疗咳嗽变异性哮喘有较好疗效.
目的 觀察囌黃止咳膠囊治療咳嗽變異性哮喘的臨床療效.方法 將80例咳嗽變異性哮喘患者完全隨機分為2組,各40例.囌黃止咳膠囊組予以囌黃止咳膠囊,每次3粒,每日3次,溫開水送服；博利康尼組予以博利康尼2.5 mg,每日3次.療程均為4週.比較2組患者療效和治療前後IgG水平及氣道阻力後.結果 囌黃止咳膠囊組治愈37例,好轉3例,治愈率為92.5％；博利康尼組治愈29例,好轉11例,治愈率為72.5％；囌黃止咳膠囊組治愈率明顯高于博利康尼組,差異有統計學意義(P＜0.05).囌黃止咳膠囊組治療前IgG水平為(6.4 ±3.2)g/L,治療後為(8.8 ±4.7)g/L,治療前後差異有統計學意義(P＜0.05)；博利康尼組治療前IgG為(6.5±2.9)g/L,治療後為(7.2±3.8) g/L,治療前後差異無統計學意義(P＞0.05)；囌黃止咳膠囊組治療後IgG水平明顯高于博利康尼組治療後(P＜0.05).囌黃止咳膠囊組治療後呼吸總阻抗、總氣道阻力、中心氣道阻力均明顯低于博利康尼組治療後[(122±36)cm H2O(1 cm H2O=0.098 kPa)比(144±41)cm H2O,(118±32)cm H2O比(142 ±35)cm H2O,(83±26)cm H2O比(100±24)cm H2O],差異均有統計學意義(均P＜0.01).結論 囌黃止咳膠囊治療咳嗽變異性哮喘有較好療效.
목적 관찰소황지해효낭치료해수변이성효천적림상료효.방법 장80례해수변이성효천환자완전수궤분위2조,각40례.소황지해효낭조여이소황지해효낭,매차3립,매일3차,온개수송복；박리강니조여이박리강니2.5 mg,매일3차.료정균위4주.비교2조환자료효화치료전후IgG수평급기도조력후.결과 소황지해효낭조치유37례,호전3례,치유솔위92.5％；박리강니조치유29례,호전11례,치유솔위72.5％；소황지해효낭조치유솔명현고우박리강니조,차이유통계학의의(P＜0.05).소황지해효낭조치료전IgG수평위(6.4 ±3.2)g/L,치료후위(8.8 ±4.7)g/L,치료전후차이유통계학의의(P＜0.05)；박리강니조치료전IgG위(6.5±2.9)g/L,치료후위(7.2±3.8) g/L,치료전후차이무통계학의의(P＞0.05)；소황지해효낭조치료후IgG수평명현고우박리강니조치료후(P＜0.05).소황지해효낭조치료후호흡총조항、총기도조력、중심기도조력균명현저우박리강니조치료후[(122±36)cm H2O(1 cm H2O=0.098 kPa)비(144±41)cm H2O,(118±32)cm H2O비(142 ±35)cm H2O,(83±26)cm H2O비(100±24)cm H2O],차이균유통계학의의(균P＜0.01).결론 소황지해효낭치료해수변이성효천유교호료효.
Objective To observe the clinical efficacy of Suhuang zhike capsule in treatment of cough variant asthma(CVA).Methods The CVA patients were randomly divided into Suhuang zhike capsule group and bricanyl group(40 cases in each group).Suhuang zhike capsule group were treated with Suhuang zhike capsule.Bricanyl group were treated with bricanyl.Two groups were treated for 4 weeks.Results The cure rate of Suhuang zhike capsule group and bricanyl group was 92.5％ (37/40),72.5％ (29/40),and there was a significant difference (P ＜ 0.05).The serum total IgG in Suhuang zhike capsule group after treatment was (8.8 ± 4.7)g/L,which was higher than that before treatment [(6.4 ± 3.2) g/L,P ＜ 0.05].The serum total IgG in bricanyl group after treatment was (7.2 ± 3.8) g/L,which was higher than that before treatment [(6.5 ± 2.9) g/L,P ＜ 0.05].The airway resistance in Suhuang zhike capsule group postoperation were lower than those in bricanyl group after treatment [(122 ±36)cm H2O (1 cm H2O =0.098 kPa) vs (144±41)cm H2O,(118 ±32)cm H2O vs(142 ±35)cm H2O,(83 ± 26)cm H2O vs (100 ± 24)cm H2O; all P ＜ 0.01].Conclusion Suhuang zhike capsule has a good effect on patients with CVA.
